{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-045722","form_type":"8-K","ticker":"BOLD","cik":"0001782303","company_name":"Boundless Bio, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.834843+00:00","generated_at":"2026-05-24T04:02:17.717575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025","bullets":["Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.","Cash and investments $152.1M as of Dec 31, 2024; projected operating runway into 2027.","BBI-355 Phase 1/2 POTENTIATE trial ongoing; initial proof-of-concept safety/activity data due H2 2025.","Novel Kinesin program: development candidate nomination targeted for mid-2025, IND submission H1 2026.","Appointed Dr. Robert Doebele as Chief Medical Officer in February 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-045722","json":"https://secwatch.observer/filing/0000950170-25-045722.json","markdown":"https://secwatch.observer/filing/0000950170-25-045722.md","text":"https://secwatch.observer/filing/0000950170-25-045722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/0000950170-25-045722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/bold-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:02:17.717575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}